Novo Nordisk’s new obesity treatment, CagriSema, led patients to lose 20.4% of their weight in a pivotal study, falling short of the company’s projected weight loss of 25%. This outcome has raised doubts about Novo Nordisk’s competitiveness in the weight loss market. The results caused Novo Nordisk’s shares to drop by over 20% in pre-market trading. The company’s next-generation obesity candidate showed promise in helping patients lose a substantial amount of weight, but the lower-than-expected results may impact Novo Nordisk’s future in the booming weight loss market.
Source link
Novo Nordisk’s next-gen obesity drug underperforms in trial
